Charlie Kim

Partner
Full contact info

"Authentic Big Law" – Can we practice law at the very highest levels, while also in a personal, caring and team-focused way that rejects discrimination and self-promotion at the cost of others, and truly reflects the ideals we hold onto so dearly outside of work? We here at Team Cooley answer that question with a resounding "yes!"

Passions

Food

K-Dramas

College Football

Experience

Uber Technologies $8.1 Billion IPO

May 11, 2019

Cooley advised Uber on its $8.1 billion initial public offering of 207,000,000 shares of common stock. Uber, whose securities now trade on the NYSE under the symbol “UBER,” is a mobility platform revolutionizing the personal ridesharing, meal delivery and logistics industries. Partners Dave Peinsipp, Siana Lowrey, Drew Williamson, Charlie Kim and Kristin VanderPas led the Cooley team.

Related contacts

David Peinsipp
Partner, San Francisco
Siana Lowrey
Partner, San Francisco
Drew Williamson
Partner, San Francisco
Charlie Kim
Partner, San Diego
Kristin VanderPas
Partner, San Francisco
Arielle H. Friehling
Associate, San Francisco
Sam Meiklejohn
Associate, London
Charles George
Associate, London

Sweetgreen – $418.6 Million IPO

December 6, 2021

Cooley advised restaurant chain sweetgreen on its $418.6 million initial public offering of 14,950,000 shares of Class A common stock, which now trade on the New York Stock Exchange under the symbol SG. Partners Nick Hobson, David Peinsipp, Siana Lowrey and Charlie Kim led the Cooley team advising sweetgreen.

Read more

Related contacts

Nick Hobson
Partner, Los Angeles Santa Monica
David Peinsipp
Partner, San Francisco
Siana Lowrey
Partner, San Francisco
Charlie Kim
Partner, San Diego
Julia Boesch
Associate, San Francisco
Mark Cikowski
Associate, Los Angeles Santa Monica
Marjorie Roesser
Associate, San Francisco
Madeleine Smith
Associate, San Francisco
Eric Steiner
Paralegal Specialist, San Francisco
Amy Saldamando
Paralegal Specialist, Los Angeles Santa Monica
Kim Merritt
Paralegal Specialist, San Francisco
Barbara Mirza
Partner, Los Angeles Santa Monica
Austin Holt
Associate, Los Angeles Santa Monica
David Navetta
Partner, Colorado
Christian Lee
Associate, San Francisco
Maricel Mojares-Moore
Special Counsel, San Francisco
Matt Kong
Associate, San Francisco
Ross Eberly
Partner, Los Angeles Santa Monica
Eileen Leman
Associate, Los Angeles Downtown
Karen Tsai
Special Counsel, Washington DC
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Stephanie Gentile
Partner, New York
John Paul Oleksiuk
Partner, New York
Colette Ghazarian
Associate, Los Angeles Downtown
Sharon Connaughton
Special Counsel, Washington DC
Patrick Gibbs
Partner, Palo Alto
Francis Wheeler
Partner, Colorado
Michael Suyat
Senior Paralegal, San Francisco

10X Genomics – $449 Million IPO

September 12, 2019

Cooley advised underwriters on 10X Genomics’ $448.5 million initial public offering of 11,500,000 shares of Class A common stock, including full exercise of the underwriters’ option to purchase additional shares. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as joint book-running managers. Cowen acted as lead manager. 10X Genomics’ securities now trade on the Nasdaq Global Select Market under the symbol “TXG.” Partners Charlie Kim, Dave Peinsipp and Kristin VanderPas led the Cooley team.

Related contacts

Charlie Kim
Partner, San Diego
David Peinsipp
Partner, San Francisco
Kristin VanderPas
Partner, San Francisco
Denny Won
Partner, San Francisco
Alexander Davis
Associate, San Diego

Lyell Immunopharma – $425 Million IPO

July 20, 2021

Cooley advised Lyell Immunopharma, a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, on its $425 million initial public offering of 25,000,000 shares of its common stock. Partners Dave Peinsipp, Charlie Kim, Chad Mills and Lauren Creel led the Cooley team advising Lyell on its public debut, which marks the third largest biotech IPO in history.

Read more

Related contacts

David Peinsipp
Partner, San Francisco
Charlie Kim
Partner, San Diego
Chadwick Mills
Partner, San Francisco
Lauren Creel
Partner, Palo Alto
Allison Peth
Associate, Palo Alto
Kristina Krasnikova
Associate, Palo Alto
Anitha Anne
Associate, San Francisco
Bill Boyle
Paralegal Specialist, Palo Alto
Marya Postner
Partner, Palo Alto
Natasha Leskovsek
Of Counsel, Washington DC
Phil Mitchell
Partner, New York
Jennifer Shanley
Special Counsel, New York
Barbara Mirza
Partner, Los Angeles Santa Monica
Austin Holt
Associate, Los Angeles Santa Monica
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Jonathan Rivinus
Partner, Colorado
Francis Wheeler
Partner, Colorado

Sana Biotechnology - $676 million IPO

Cooley advised the underwriters on Sana Biotechnology’s $676 million initial public offering of 27,025,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and BofA Securities, Inc. acted as the joint book-running managers for the offering. Sana Biotechnology, whose securities now trade on the Nasdaq Global Market under the symbol “SANA,”  is a company focused on creating and delivering engineered cells as medicines. Partners Charlie Kim, Dave Peinsipp and Kristin VanderPas led the Cooley team.

Related contacts

Charlie Kim
Partner, San Diego
David Peinsipp
Partner, San Francisco
Kristin VanderPas
Partner, San Francisco
Denny Won
Partner, San Francisco
Julia Gage
Associate, San Francisco
View more

Charlie Kim skillfully navigating your capital markets transactions - priceless. Charlie's depth and breadth of knowledge/experience was crucial in the successful execution of our IPO and multiple follow-on offerings which tallied to over $1.2 billion. Internally, we nicknamed Charlie the 'Ironman of Capital Markets'. He and his team were a pleasure to partner with from the pre-planning phase all the way through the end of the process.

Tom Walker, former CFO of Tableau Software

Rankings & accolades

Daily Journal: California Lawyer Attorneys of the Year; Top 100 Lawyer in California

Chambers USA: Capital Markets: Debt & Equity – Nationwide (Western United States) (Band 1)

Law 360: Capital Markets MVP

Legal 500: Leading Lawyer - Capital Markets: Equity Offerings; Next Generation Lawyer - Capital Markets: Equity Offerings

Thomas Reuters: San Diego & Southern California Super Lawyer

The Daily Transcript: San Diego Top Attorney

Memberships & affiliations

American Bar Association

New York State Bar Association

San Diego County Bar Association

Representative Issuers

Charlie has represented companies/investment banks on capital market transactions involving issuers across industries, such as: AbCellera, Accelerate, Acutus, Advaxis, Aerohive, Agenus, Akari, Akcea, Akero, Allogene, Alteryx, Ambrx, Amylin, Anadys, AnaptysBio, Angion, Annexon, Anthera, Apigee, Applied Molecular Transport, Arcadia, Arcus, Arcutis, Ardea, Arena, Aridis, Ascendis, ASLAN, Athira, Audentes, Avidity, Ballast Point Brewing & Spirits, Biomea, Cadence, Castlight, Cerus, Cidara, Clorox, Corcept, Crinetics, Cue Health, Cyan, Cytori, Day One, Dermira, Design, DICE, Doximity, Dynavax, eBay, EHang, Eidos, Elevation Oncology, Entropic, Erasca, Exagen, Evofem, Fangdd, FIGS, FireEye, Five Prime, Gemphire, Genomatica, Global Blood Therapeutics, Gossamer, Gracell, Graphite Bio, Gritstone, Guardant Health, Halozyme, Health Catalyst, Healthcare Royalty, HealthEquity, Horizon, IGM, Ignyta, Immune Design, IMV, Inhibrx, Inovio, Insys, Invitae, Ionis, Janux, Jazz Pharmaceuticals, Kamada, Kinnate, Kite Pharma, Kronos, Landry's, LifeLock, Limelight, Livongo, Longboard, Lyell, MannKind, Medallia, MethylGene, Metropark, MindBody, Minerva, Mirati, NantHealth, NantKwest, Nektar, Neon, Neurocrine, ObsEva, Olink, Ooma, Optimer, ORIC, Otonomy, Pernix, Phathom, Poseida, PRA Holdings, PROCEPT, Progressive Gaming, ProNAi, ProQR, Proto Labs, Qualtrics, Quidel, Radiant Systems, Rani, Raptor, Reata, Receptos, Regulus, ReSearch Pharmaceutical Services, Sana, Sangamo, Santarus, Seattle Genetics, Senomyx, Sequenom, ShockWave, Sierra, Silverback, Singular Genomics, Somaxon, Strongbridge, Surface Oncology, Sutro, Syndax, Tableau Software, Tabula Rasa, Taiwan Liposome Company, Tangoe, TRACON, Treace, Tricida, Trius, TriVascular Technologies, Uber Technologies, Vaxcyte, Ventyx Biosciences,, Verenium, Verona, Vical, ViewRay, Vir, Vital Therapies, Vor, Xencor, Xenon, XenoPort, Zealand Pharma, Zentalis, Zogenix, Zscaler, Zymeworks, 4D Molecular Therapeutics,10x Genomics and 89bio.